Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

LaBranche, Celia C., Rory Henderson, Allen Hsu, Shay Behrens, Xuejun Chen, Tongqing Zhou, Kevin Wiehe, et al. “Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.” Plos Pathog 15, no. 12 (December 2019): e1008200. https://doi.org/10.1371/journal.ppat.1008200.

Full Text

Sliepen, K., B. W. Han, I. Bontjer, P. Mooij, F. Garces, A. J. Behrens, K. Rantalainen, et al. “Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.” In Nature Communications, Vol. 10, 2019. https://doi.org/10.1038/s41467-019-10262-5.

Full Text

Pinto, Dora, Craig Fenwick, Christophe Caillat, Chiara Silacci, Serafima Guseva, François Dehez, Christophe Chipot, et al. “Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.” Cell Host Microbe 26, no. 5 (November 13, 2019): 623-637.e8. https://doi.org/10.1016/j.chom.2019.09.016.

Full Text

Kibler, Karen V., Benedikt Asbach, Beatriz Perdiguero, Juan García-Arriaza, Nicole L. Yates, Robert Parks, Sherry Stanfield-Oakley, et al. “Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC".” J Virol 93, no. 21 (November 1, 2019). https://doi.org/10.1128/JVI.00968-19.

Full Text

Rouphael, Nadine G., Cecilia Morgan, Shuying S. Li, Ryan Jensen, Brittany Sanchez, Shelly Karuna, Edith Swann, et al. “DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.” J Clin Invest 129, no. 11 (November 1, 2019): 4769–85. https://doi.org/10.1172/JCI128699.

Full Text

Pantaleo, Giuseppe, Holly Janes, Shelly Karuna, Shannon Grant, G Laissa Ouedraogo, Mary Allen, Georgia D. Tomaras, et al. “Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.” Lancet Hiv 6, no. 11 (November 2019): e737–49. https://doi.org/10.1016/S2352-3018(19)30262-0.

Full Text

Gach, Johannes S., Kane J. V. Mara, Celia C. LaBranche, Marit J. van Gils, Laura E. McCoy, P. J. Klasse, David C. Montefiori, Rogier W. Sanders, John P. Moore, and Donald N. Forthal. “Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.” J Virol 93, no. 20 (October 15, 2019). https://doi.org/10.1128/JVI.01188-19.

Full Text

Styles, Tiffany M., Sailaja Gangadhara, Pradeep B. J. Reddy, Sakeenah Hicks, Celia C. LaBranche, David C. Montefiori, Cynthia A. Derdeyn, Pamela A. Kozlowski, Vijayakumar Velu, and Rama Rao Amara. “Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.” J Virol 93, no. 20 (October 15, 2019). https://doi.org/10.1128/JVI.00934-19.

Full Text

Gorman, Jason, Rosemarie D. Mason, Leonard Nettey, Nicole Cavett, Gwo-Yu Chuang, Dongjun Peng, Yaroslav Tsybovsky, et al. “Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields.” Immunity 51, no. 4 (October 15, 2019): 724-734.e4. https://doi.org/10.1016/j.immuni.2019.09.007.

Full Text

Brouwer, Philip J. M., Aleksandar Antanasijevic, Zachary Berndsen, Anila Yasmeen, Brooke Fiala, Tom P. L. Bijl, Ilja Bontjer, et al. “Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle.” Nat Commun 10, no. 1 (September 19, 2019): 4272. https://doi.org/10.1038/s41467-019-12080-1.

Full Text

Pages